Literature DB >> 22788991

Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant AdΔΔ and Dietary Phytochemicals in Prostate Cancer Models.

Virginie Adam1, Maria Ekblad, Katrina Sweeney, Heike Müller, Kristina Hammarén Busch, Camilla Tørnqvist Johnsen, Na Ra Kang, Nick R Lemoine, Gunnel Halldén.   

Abstract

AdΔΔ is an oncolytic adenoviral mutant that has been engineered to selectively target tumors with deregulated cell cycle and apoptosis pathways. AdΔΔ potentiates apoptotic cell death induced by drugs, including mitoxantrone and docetaxel, which are commonly used to treat prostate cancer. Here, we demonstrate that AdΔΔ can also interact synergistically with dietary phytochemicals known to have anti-cancer activities, without incurring the toxic side effects of chemodrugs. Curcumin, genistein, epigallocatechin-gallate, equol, and resveratrol efficiently killed both androgen-receptor positive (22Rv1) and negative cell lines (PC-3, DU145) in combination with adenoviral mutants. Synergistic cell killing was demonstrated with wild-type virus (Ad5) and AdΔΔ in combination with equol and resveratrol. EC(50) values for both phytochemicals and viruses were reduced three- to eightfold in all three combination-treated cell lines. The most potent efficacy was achieved in the cytotoxic drug- and virus-insensitive PC-3 cells, both in vitro and in vivo, while cell killing in normal bronchial epithelial cells was not enhanced. Although equol and resveratrol induced only low levels of apoptosis when administered alone, in combination with wild-type virus or AdΔΔ, the level of apoptotic cell death was significantly increased in PC-3 and DU145 cells. In vivo studies using suboptimal doses of AdΔΔ and equol or resveratrol, showed reduced tumor growth without toxicity to normal tissue. These findings identify novel functions for AdΔΔ and phytochemicals in promoting cancer cell killing and apoptosis, suggesting the use of these natural nontoxic compounds might be a feasible and currently unexploited anti-cancer strategy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22788991      PMCID: PMC3440020          DOI: 10.1089/hum.2012.046

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  46 in total

1.  Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.

Authors:  Clodagh C O'Shea; Leisa Johnson; Bridget Bagus; Serah Choi; Cory Nicholas; Annie Shen; Larry Boyle; Kusum Pandey; Conrado Soria; John Kunich; Yuqiao Shen; Gaston Habets; Dave Ginzinger; Frank McCormick
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

Review 2.  Recent progress in the battle between oncolytic viruses and tumours.

Authors:  Kelley A Parato; Donna Senger; Peter A J Forsyth; John C Bell
Journal:  Nat Rev Cancer       Date:  2005-12       Impact factor: 60.716

3.  China approves world's first oncolytic virus therapy for cancer treatment.

Authors:  Ken Garber
Journal:  J Natl Cancer Inst       Date:  2006-03-01       Impact factor: 13.506

Review 4.  Resveratrol as an anticancer nutrient: molecular basis, open questions and promises.

Authors:  Paola Signorelli; Riccardo Ghidoni
Journal:  J Nutr Biochem       Date:  2005-08       Impact factor: 6.048

Review 5.  Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis.

Authors:  Sandra Ulrich; Freya Wolter; Jürgen M Stein
Journal:  Mol Nutr Food Res       Date:  2005-05       Impact factor: 5.914

6.  Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.

Authors:  Jeanette Dilley; Seshidhar Reddy; Derek Ko; Natalie Nguyen; Ginny Rojas; Peter Working; De-Chao Yu
Journal:  Cancer Gene Ther       Date:  2005-08       Impact factor: 5.987

7.  Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.

Authors:  M Raki; A Kanerva; A Ristimaki; R A Desmond; D-T Chen; T Ranki; M Sarkioja; L Kangasniemi; A Hemminki
Journal:  Gene Ther       Date:  2005-08       Impact factor: 5.250

8.  A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

Authors:  Eric J Small; Michael A Carducci; James M Burke; Ron Rodriguez; Lawrence Fong; Lynn van Ummersen; D C Yu; Junko Aimi; Dale Ando; Peter Working; David Kirn; George Wilding
Journal:  Mol Ther       Date:  2006-05-09       Impact factor: 11.454

9.  Adenovirus overrides cellular checkpoints for protein translation.

Authors:  Clodagh C O'Shea; Serah Choi; Frank McCormick; David Stokoe
Journal:  Cell Cycle       Date:  2005-07-02       Impact factor: 4.534

10.  Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus.

Authors:  Hideaki Ito; Hiroshi Aoki; Florian Kühnel; Yasuko Kondo; Stefan Kubicka; Thomas Wirth; Eiji Iwado; Arifumi Iwamaru; Keishi Fujiwara; Kenneth R Hess; Frederick F Lang; Raymond Sawaya; Seiji Kondo
Journal:  J Natl Cancer Inst       Date:  2006-05-03       Impact factor: 13.506

View more
  9 in total

Review 1.  The biological functions of Naa10 - From amino-terminal acetylation to human disease.

Authors:  Max J Dörfel; Gholson J Lyon
Journal:  Gene       Date:  2015-05-16       Impact factor: 3.688

2.  Microfluidic System Based High Throughput Drug Screening System for Curcumin/TRAIL Combinational Chemotherapy in Human Prostate Cancer PC3 Cells.

Authors:  Dami An; Kwangmi Kim; Jeongyun Kim
Journal:  Biomol Ther (Seoul)       Date:  2014-07       Impact factor: 4.634

3.  Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy.

Authors:  Carmen Aguirre-Hernández; Héctor Maya-Pineda; Julia San Millán; Y K Stella Man; Yong-Jie Lu; Gunnel Halldén
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

4.  Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models.

Authors:  Yang Kee Stella Man; Carmen Aguirre-Hernandez; Adrian Fernandez; Pilar Martin-Duque; Rebeca González-Pastor; Gunnel Halldén
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

5.  Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer.

Authors:  Saswati Banerjee; Santosh K Singh; Indrajit Chowdhury; James W Lillard; Rajesh Singh
Journal:  Front Biosci (Elite Ed)       Date:  2017-03-01

Review 6.  Resveratrol in prostate diseases - a short review.

Authors:  Milosz Jasiński; Lidia Jasińska; Marcin Ogrodowczyk
Journal:  Cent European J Urol       Date:  2013-08-13

7.  Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice.

Authors:  Yue-Hong Shen; Fei Yang; Hua Wang; Zhi-Jian Cai; Yi-Peng Xu; An Zhao; Ying Su; Gu Zhang; Shao-Xing Zhu
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

8.  The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.

Authors:  Effrosyni Tsafa; Mariam Al-Bahrani; Kaoutar Bentayebi; Justyna Przystal; Keittisak Suwan; Amin Hajitou
Journal:  Oncotarget       Date:  2016-08-09

Review 9.  Designer Oncolytic Adenovirus: Coming of Age.

Authors:  Alexander T Baker; Carmen Aguirre-Hernández; Gunnel Halldén; Alan L Parker
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.